CRISPR Therapeutics AG (CRSP) Advances But Underperforms Market: Key Facts
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $38.25, moving +1.38% from the previous trading session.
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
2 Beaten-Down Stocks With Incredible Upside Potential
Iovance Biotherapeutics (IOVA -1.52%) and CRISPR Therapeutics (CRSP -1.27%) are two incredibly innovative biotechs, but this hasn't translated into strong performances recently. Both stocks have significantly lagged the market over the past three years due to a combination of factors.
CRISPR Therapeutics AG (CRSP) Advances But Underperforms Market: Key Facts
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $39.11, marking a +1.48% move from the previous day.
CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know
In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $38.54, denoting a -1.76% change from the preceding trading day.
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $37.77, representing a -0.03% change from its previous close.
3 Magnificent Stocks That Could Double or More by 2030
When the stock market is as turbulent as it is these days, it's easy to forget the times when things are decidedly more cheery. However, sell-offs present great opportunities to buy stocks with significant upside potential.
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
CRISPR Therapeutics AG (CRSP) Annual Needham Virtual Healthcare Conference (Transcript)
CRISPR Therapeutics AG (NASDAQ:CRSP ) Annual Needham Virtual Healthcare Conference Call April 8, 2025 12:45 PM ET Company Participants Sam Kulkarni - Chief Executive Officer Conference Call Participants Gil Blum - Needham & Company Gil Blum Good afternoon, everyone, and thank you for joining me at the second day of the Needham Healthcare conference. My name is Gil Blum, and I am senior biotech analyst here at Needham & Company with a focus on immune-oncology.
4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street
As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like a year, thanks to excellent clinical or regulatory progress. And based on Wall Street's projections, several notable biotechs could see their shares soar in the next 12 months.
Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr.
The decline in biotech stocks comes after FDA official Peter Marks' resignation, citing irreconcilable differences with the new HHS Secretary.
